Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
| Original language | English |
|---|---|
| Pages (from-to) | 1593-1603 |
| Number of pages | 11 |
| Journal | Diabetes Care |
| Volume | 42 |
| Issue number | 8 |
| DOIs | |
| State | Published - 1 Aug 2019 |
Funding
| Funders | Funder number |
|---|---|
| Becton Dickinson | |
| National InstitutesofHealth | |
| diaTribe Foundation | |
| National Cancer Institute | |
| National Institute of Diabetes and Digestive and Kidney Diseases | |
| Eli Lilly and Company | |
| Merck | |
| Roche | |
| Sanofi | |
| Medtronic | |
| National Center for Advancing Translational Sciences | UL1TR001863 |
| Juvenile Diabetes Research Foundation United States of America | |
| Abbott Diabetes Care | |
| Jaeb Center for Health Research | |
| Novo Nordisk | |
| Roche Diabetes Care |